ACE2 and COVID-19: The clear centrality of ACE2 and therefore of RAS to COVID-19 provide the rationale for our prevalence of COVID-19 survey in GS/BS patients as they all share a characteristic endogenously increased ACE2, ROCK inhibition, and activation of anti-inflammatory and antioxidant defenses (4, 5).